This Data Descriptor provides a reusable non-human primate proteomic resource for tissue-resolved analysis and comparison of tau-associated molecular features.
Abstract
Tau pathology is a defining feature of several neurodegenerative disorders, but reusable proteomic resources from non-human primate tauopathy models remain limited. Here we describe a four-dimensional label-free quantitative proteomic dataset from cortex and spinal cord tissues of wild-type and Tau-P301L transgenic cynomolgus macaques. The dataset comprises 16 neural tissue samples from four wild-type and four Tau-P301L animals, with paired cortical and spinal cord specimens collected from each monkey. Samples were analysed by LC-MS/MS on a Bruker timsTOF Pro platform, and label-free quantification was performed with MaxQuant against a Macaca fascicularis UniProt protein database. In total, 6,632 protein-group entries were identified, of which 6,520 protein groups were retained in the analysis-ready matrix for quality control and reuse. The accompanying records include raw mass spectrometry files, processed expression matrices, sample metadata and analysis scripts. This Data Descriptor provides a reusable non-human primate proteomic resource for tissue-resolved analysis and comparison of tau-associated molecular features.
Together, these results map compartment-specific signatures of senescence and early neuropathology across the non-human primate (NHP) lifespan and support the use of NHP models in translational biomarker studies.
Giovanne B. Diniz, Kayla Schwartz, Carissa T. Erices et al.· GeroScience· 0 citations
Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer's disease. However, the molecular basis underlying their spatial heterogeneity and biochemical complexity remain unclear. To address this, we performed mass spectrometry-based proteomic profiling of two neocortical regions with different susceptibilities to NFT...
Xue-Mei Zeng, E. Abrahamson, W. G. Balogun et al.· medRxiv· 0 citations
Tau phosphorylation at threonine 217 (pT217) has been increasingly recognized as a biomarker for Alzheimer disease (AD), but its neuropathological distribution and the performance of available antibodies remain to be fully characterized. In this study, we performed a comparative evaluation of a recombinant rabbit monoc...
Emi Higashiizumi, Hiroshi Shimizu, Takaaki Nishikawa et al.· Journal of Neuropathology an...· 0 citations
Background/Objectives: Affinity proteomics of amyloid precursor protein (APP) is complicated by proteolytic processing, dynamic trafficking, and purification background. We generated a C-terminal 3×FLAG knock-in at the endogenous App locus to establish a cortical affinity-proteomic resource and prioritize APP-associate...
Ye-Ting Zeng, Shu-Shan Wei, Ke-Yi Hu et al.· Biomedicines· 0 citations
Blood phosphorylated tau 217 (p-tau217) accurately detects Alzheimer’s disease (AD) pathology but is also elevated in amyotrophic lateral sclerosis (ALS), likely reflecting peripheral (big) tau released from muscle. Assays selectively measuring brain-derived (BD-) tau and BD-p-tau217 are therefore needed. We analysed s...
S. Abu-Rumeileh, H. Großkopf, Arthur Guthknecht et al.· Nature Communications· 0 citations
Data suggest an increase in neuronal excitability in P301L mice compared with WT, but that this phenotype is not correlated with the age-dependent accumulation of AT8-labeled tau aggregates and the accompanying neuroinflammation.
K. Dunton, Hugo Monchal, Brie E Achorn et al.· Frontiers in Neuroscience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.